RT Journal Article
SR Electronic
T1 Declines in Influenza Vaccination Coverage in White and Black, Non-Hispanic Children from 2012-2019 to 2019-2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.08.23290565
DO 10.1101/2023.06.08.23290565
A1 Corle, Abigail L.
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.08.23290565.abstract
AB Declines in routine influenza vaccination rates have become a cause for concern as influenza vaccine coverage rates have declined among Black, Non-Hispanic children compared to an increase in coverage among White, Non-Hispanic children ages 6 months to 17 years old. Influenza season years analyzed were 2012-2022 using data provided by the US Center for Disease Control’s FluVaxView database. Data for this database is sourced from the National Immunization Survey-Flu (NIS-Flu) and the Behavioral Risk Factor Surveillance System (BRFSS) survey. White, Non-Hispanic children saw an increase in vaccination coverage from 55.8% to 60.3%, whereas Black, Non-Hispanic children decreased from 58.2% to 52.9% coverage. Chi-squared tests with Yates correlation were performed to find statistical significance. Vaccination coverage rate changes for both demographics were found to be statistically significant at p < 0.00001. 70% influenza vaccination coverage rate remains the US Department of Health’s HealthyPeople 2030 initiative’s goal for all demographics and may be achieved by utilizing interventional tools such as motivational interviewing, provider-patient dialogue, community-based vaccination clinics, or home visits. Evidence-based interventional provider-patient dialogue has had success in increasing vaccination rates among other vaccines. Continued research into the cause of influenza vaccination rate decline among vulnerable and medically underserved populations is needed to best implement vaccine-based interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://www.cdc.gov/flu/excel/fluvaxview/2022/OnlineReport_2021_22_AdditionalTable_FluVxByRaceAndAge_Children.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2021/general_population/OnlineReport_2020_21_AdditionalTable_FluVxByRaceAndAge_Children-10_5_21.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2020/general_population/OnlineReport_2019_20_AdditionalTable_FluVxByRaceAndAge_Children-v2.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2019/general_population/OnlineReport_2018_19_AdditionalTable_FluVxByRaceAndAge_Children-cor-ver.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2018/children/OnlineReport_2017_18_AdditionalTable_FluVxByRaceAndAge_Children-Cor-Ver.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2017/general_population/coverage-supplement-table-6.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2016/2015-16_coverage_supplemental-1.xlsx https://www.cdc.gov/flu/excel/fluvaxview/sep-2015/2014-15_coverage_supplemental-1.xlsx https://www.cdc.gov/flu/excel/fluvaxview/sep-2014/2013-14_coverage_supplemental-1.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2012-13_coverage_supplemental-1.xlsxI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available on request to the author. https://www.cdc.gov/flu/excel/fluvaxview/2022/OnlineReport_2021_22_AdditionalTable_FluVxByRaceAndAge_Children.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2021/general_population/OnlineReport_2020_21_AdditionalTable_FluVxByRaceAndAge_Children-10_5_21.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2020/general_population/OnlineReport_2019_20_AdditionalTable_FluVxByRaceAndAge_Children-v2.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2019/general_population/OnlineReport_2018_19_AdditionalTable_FluVxByRaceAndAge_Children-cor-ver.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2018/children/OnlineReport_2017_18_AdditionalTable_FluVxByRaceAndAge_Children-Cor-Ver.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2017/general_population/coverage-supplement-table-6.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2016/2015-16_coverage_supplemental-1.xlsx https://www.cdc.gov/flu/excel/fluvaxview/sep-2015/2014-15_coverage_supplemental-1.xlsx https://www.cdc.gov/flu/excel/fluvaxview/sep-2014/2013-14_coverage_supplemental-1.xlsx https://www.cdc.gov/flu/excel/fluvaxview/2012-13_coverage_supplemental-1.xlsx